Related Experiment Video
Updated: Jul 5, 2026
08:03
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
Published on: June 6, 2018
Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction
W Wallace Dinsmore1, Michael G Wyllie
1Royal Victoria Hospital, Belfast, UK.
BJU International
|May 20, 2008
Summary
Invicorp, a combination therapy for erectile dysfunction (ED), offers an effective alternative for men unresponsive to oral treatments. This intracavernosal injection therapy demonstrates high efficacy with minimal side effects like pain or priapism.
Area of Science:
- Urology
- Pharmacology
Background:
- Erectile dysfunction (ED) affects many men, with oral therapies being ineffective or contraindicated for a significant portion.
- Intracavernosal injection (ICI) therapy presents a highly effective nonsurgical treatment option for ED.
Purpose of the Study:
- To evaluate the efficacy and safety of Invicorp, an intracavernosal injection therapy for moderate to severe erectile dysfunction.
- To assess Invicorp as an alternative for patients who have not responded to oral ED treatments.
Main Methods:
- Invicorp is an intracavernosal injection combining vasoactive intestinal polypeptide (VIP) and phentolamine mesylate.
- VIP enhances the veno-occlusive mechanism, while phentolamine increases arterial blood flow, offering complementary actions.
Main Results:
- Clinical studies indicate Invicorp is effective in 80% or more of men with ED, including those refractory to other therapies.
- Invicorp exhibits a very low incidence of penile pain and a negligible risk of priapism compared to existing treatments.
Conclusions:
- Invicorp provides a safe and effective intracavernosal injection treatment for moderate to severe ED.
- This therapy is a viable alternative for the estimated over 5.9 million men in the USA for whom oral ED drugs are not suitable.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:17Male Sexual Response: Erection & Ejaculation
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...